Trial Profile
A Prospective, Controlled, Double Blind, Multi-Center, Randomized, 3 Arm, Phase 1b/2a Study to Assess the Safety, Tolerability, and Preliminary Efficacy of B244 Delivered as an Intranasal Spray in Healthy Volunteers and Subjects With Seasonal Allergic Rhinitis
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 27 Nov 2022
Price :
$35
*
At a glance
- Drugs B 244 (Primary)
- Indications Seasonal allergic rhinitis
- Focus Adverse reactions
- Sponsors AOBiome
- 03 Jun 2019 Status changed from active, no longer recruiting to completed.
- 14 Mar 2019 Planned End Date changed from 1 Dec 2018 to 1 May 2019.
- 14 Mar 2019 Status changed from recruiting to active, no longer recruiting.